Prednisolone and Vitamin B1/6/12 in Patients With Post-Covid-Syndrome — PreVitaCOV  

Post-COVID-19 Syndrome Clinical Trial

Official title: Prednisolone and Vitamin B1, B6, and B12 in Patients With Post-COVID-19-Syndrome (PC19S) - a Randomized Controlled Trial in Primary Care

Status Recruiting

Clinical Trial Summary

This is a multicenter, randomized, placebo controlled, double-blind phase III trial with four parallel groups studying studying the feasibility of RCT in primary care as well as the effectiveness of treatment with prednisolone and/or vitamin B1/6/12 for PC19S.

Clinical Trial Description

PC19S affects a considerable portion of patients after an infection with SARS-CoV-2 with a broad range of disabling symptoms. Neurotropic vitamins such as vitamins B1, B6, an B12, and drugs with anti-inflammatory properties such as corticosteroids were suggested to alleviate symptoms. The trial is designed as a two-step approach that will

1. prove the feasibility of recruitment and retention of patients with PC19S in a primary care setting (pilot study, n=100)

2. investigate the effectiveness and safety of the treatment drugs alone and of their combination (confirmatory study, n= 340).

The pilot study will be transformed into a confirmatory study if feasibility is given, defined as retention rate of 85% after enrollment of 100 patients. Or on recommendation of the Data Safety and Monitoring Board (DSMB).

In addition, blood samples wil be analysed for routine parameters and vitamin B12 derivates as well as cytokines. ;

Related Conditions & MeSH terms

• COVID-19
• Post-COVID-19 Syndrome
• Syndrome

• NCT number: NCT05638633
• Study type: Interventional
• Source: Wuerzburg University Hospital
• Contact: Andreas Klug
• Phone: 0931-20147803
• Email: Klug_A1@ukw.de
• Status: Recruiting
• Phase: Phase 3
• Start date: November 11, 2022
• Completion date: December 31, 2024